Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash Flows from Operating Activities
Net income (loss)	$ (4,929)	$ 1,624
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	12,009	11,568
Gain on sale of bioplastics manufacturing business	(1,453)	0
Gain on sale of joint venture interest	0	(4,055)
Loss/(gain) on sale of assets	47	(832)
Share based compensation	932	969
Equity in loss	204	301
Deferred income taxes, including change in valuation allowance	(152)
Changes in operating assets and liabilities:
Restricted cash	12	7,593
Receivables, net	7,511	(7,521)
Inventory	1,542	(5,450)
Prepaid expenses	(129)	261
Refundable income taxes	(224)	324
Accounts payable	2,571	(4,302)
Accounts payable to affiliate, net	(2,804)	(2,159)
Accrued expenses	3,264	593
Change in derivatives	0	(2,034)
Deferred credit	(208)	(630)
Accrued retirement health and life insurance benefits and other noncurrent liabilities	(876)	(1,081)
Other	(17)	(195)
Net cash provided by (used in) operating activities	17,300	(5,026)
Cash Flows from Investing Activities
Additions to property and equipment	(6,208)	(9,229)
Investments in/ advances to equity method investments	0	(500)
Proceeds from sale of bioplastics manufacturing business	2,797	0
Proceeds from sale of interest in ICP, net	0	9,103
Proceeds from disposition of property and Equipment	0	3,263
Other	0	568
Net cash provided by (used in) investing activities	(3,411)	3,205
Cash Flows from Financing Activities
Payment of dividends	(916)	(914)
Purchase of treasury stock	(540)	(84)
Loan fees incurred with borrowings	0	(644)
Principal payments on long-term debt	(1,683)	(1,671)
Proceeds from revolving credit facility	95,512	127,089
Principal payments on revolving credit facility	(103,405)	(122,338)
Net cash provided by (used in) financing activities	(11,032)	1,438
Increase (decrease) in cash and cash equivalents	2,857	(383)
Cash and cash equivalents, beginning of year	0	383
Cash and cash equivalents, end of year	$ 2,857	$ 0